Core Viewpoint - NAYA Biosciences, Inc. will implement a 1-for-12 reverse stock split to comply with Nasdaq's minimum bid price requirement, effective March 18, 2025 [1][3]. Company Overview - NAYA Biosciences is focused on developing breakthrough treatments in oncology, autoimmune diseases, and women's health, and is a leading provider of IVF and IVC fertility treatments [1][4]. - The company utilizes a hub & spoke model to optimize the acquisition, development, and partnering of assets, aiming for efficient returns on investment [4]. Reverse Stock Split Details - The reverse stock split will convert every 12 shares of common stock into 1 share, rounding up any fractional shares [2]. - Post-split, the company will have approximately 666,057 shares issued and outstanding, with authorized shares adjusted to 4,166,666 [2]. Compliance and Market Position - The primary goal of the reverse stock split is to meet Nasdaq's $1.00 per share minimum bid price requirement for continued listing, although success is not guaranteed [3]. - NAYA's current portfolio includes innovative therapies targeting significant market needs, such as hepatocellular carcinoma and multiple myeloma [5].
NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025